Amphotericin B is a current Gold Standard drug for the treatment of systemic fungal infections, but is only available in IV formulation and not practical in most third-world situations. In regions where fungal infections such as candidiasis, histoplasmosis and aspergillosis are rampant, particularly in patients suffering from cancer, diabetes and HIV/AIDS, an oral formulation would be optimal and also applicable for outpatients to self administer.

Dr. Kishor Wasan has been working with iCo Therapeutics on the development of a proprietary, lipid-based Amp B formulation for oral administration. Initial data from both cell lines and in vivo research indicate that it is highly efficacious and exhibits low toxicity within the dosage range required for the treatment of diseases such as disseminated fungal infections and Leishmaniasis. The Oral Delivery System: Amphotericin B has been granted Orphan Drug status for the treatment of Visceral Leishmaniasis (VL) by the US Food and Drug Administration (FDA).

**POTENTIAL INDICATIONS**

**Developed World: Anti-Fungal**
- HIV latent reservoirs
- Systemic Fungal Infections
  - Immune-compromised patients: Cancer, HIV/AIDS, Diabetes, Transplantation

**Developing World: Anti-Parasitic**
- Visceral Leishmaniasis
  - 2nd largest parasitic killer after malaria
  - 500,000 new infections every year
  - Fatal if left untreated

**PRODUCT HIGHLIGHTS**
- Lipid capsule “Candy Wrapper”
- Expanding the Amphotericin B market: safety and convenience
- Oral treatment goal of global health organizations including Gates Foundation & WHO
- Approximately $2 million in committed non-dilutive funding (CPDD/Gates Foundation and CIHR)
- Proprietary platform may be used for other insoluble products
- Orphan drug status received for Visceral Leishmaniasis
- Significant and growing IP portfolio

**RECENT & UPCOMING MILESTONES**
- Orphan Drug Status received for Visceral Leishmaniasis
- In vitro testing
- IND filing in H2 2015
- Phase 1A clinical study initiation Q1 2016
- Phase 1A final data Q3 2016
- Ongoing partnership discussions